Clinical Trial Update: Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor [Phase 4]

View source ↗

Summary

A Phase 4 trial exploring whether rifaximin-induced modulation of gut microbiota can reduce high platelet reactivity in post-acute coronary syndrome patients tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction

Drugs mentioned

• Rifaximin (rifaximin)
• TICAGRELOR (ticagrelor)

Snippet

Sponsor: Collegium Medicum w Bydgoszczy | Conditions: ACS - Acute Coronary Syndrome, Ticagrelor | Phase 4 | Status: NOT_YET_RECRUITING